Down 10% in a day! The GSK share price looks like a once-in-a-decade bargain buy

Harvey Jones didn’t waste a second before taking advantage of a sharp drop in the GSK share price on Monday. Then the doubts set in.

| More on:
A GlaxoSmithKline scientist uses a microscope

Image: GlaxoSmithKline

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I love buying stocks on bad news, so when I logged on this Monday to find the GSK (LSE: GSK) share price had fallen 9.53%, I snapped up its shares right away.

It’s a policy of mine to average down on portfolio holdings when bad news strikes. The only times I didn’t do that last year – with Glencore and Unilever – I was soon kicking myself as they recovered.

I was so keen to avoid a repeat that I filled my boots without discovering why GSK had slumped. In my defence, it was Monday. I was busy. The stock was trading at a 10% discount to Friday. Seriously, what could go wrong?

FTSE 100 bargain?

I’m not always so rash with my money. And I won’t be again. When I found out what triggered the crash, I had second thoughts but then it was too late

GSK’s value fell by £7bn after a Delaware judge gave the go-ahead to 70,000 lawsuits alleging that its discontinued heartburn drug Zantac caused cancer. The group immediately said it would appeal, arguing there is “no consistent or reliable evidence” to suggest cancer risk.

This was a real shock. One week earlier, a jury in Illinois has ruled in favour of GSK in the first Zantac case to go to trial. Worse, JP Morgan said the potential liability could top the $2bn to $3bn figure previously assumed by the market. The only positive is that a defeat would probably end in a settlement rather than 70,000 individual claims, which would be off the chart, compensation-wise.

Either way, the uncertainty extends a tough decade for GSK, formerly GlaxoSmithKline, which is still battling to replenish its drugs pipeline. Its once mighty dividend was frozen at 80p per share for years, then cut to 44p in 2022, then 42p in 2023. 

Even hiving off its consumer healthcare division, Haleon hasn’t shifted the dial. Now it’s going to fall even further behind all-conquering FTSE 100 rival AstraZeneca.

Bargain stock opportunity

Yet I bought more shares in the company without asking what was up? Thankfully, the shares didn’t fall any further on Monday. In fact, they jumped 1.06% on Tuesday and 2.16% on Wednesday. Sheer dumb luck on my part. I could sell Monday’s purchase at a tiny profit, after stamp duty and charges.

I won’t do that, though. GSK shares look decent value trading at 11.7 times forecast earnings. They’re up 18.09% over the last year, despite this week’s volatility.

The yield isn’t great at 3.76%, roughly in line with the FTSE 100 average, but it’s okay. I don’t have any other direct exposure to the healthcare sector, and I don’t fancy buying AstraZeneca at today’s far higher valuation of 41.26 times earnings.

Yes, GSK could lose that court case. Much of the risk is priced in. The shares are now trading at the same level as they did 10 years ago. The next decade has to be better, doesn’t it? Although, next time a portfolio holding drops 10%, I’ll do my research before loading up.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has positions in GSK. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

9.4%+ yields! 3 proven FTSE 100 dividend payers I’d buy for my Stocks and Shares ISA

Our writer highlights a trio of FTSE 100 shares with yields close to 10%. He'd happily pop them into his…

Read more »

Mixed-race female couple enjoying themselves on a walk
Investing Articles

Are Raspberry Pi shares a once-in-a-lifetime chance to get rich?

With Raspberry Pi shares surging after a successful IPO, could this UK tech startup offer a long-term wealth creation opportunity…

Read more »

Newspaper and direction sign with investment options
Investing Articles

Huge gains and 9% yields: why now’s an amazing time to be a stock market investor

The stock market’s generating fantastic returns in 2024. Whether you're looking for gains or income, it’s a great time to…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

This steady dividend payer looks like one of the best bargain stocks in the FTSE 100

A yield of 4.7% and a consistent dividend record make this FTSE 100 company look like good value in an…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

£9,000 in savings? That could become passive income of £19,175 a year

It's possible to invest affordable sums of money into building a big passive income stream. Here's how I'd go about…

Read more »

Black father and two young daughters dancing at home
Investing Articles

Legal & General shares: a once-in-a-decade passive income opportunity?

Is a dividend yield at its highest level in a decade, combined with a strong record of increasing payouts, a…

Read more »

Investing Articles

With a 7% yield and 4.1 P/E, is this the best passive income stock on the FTSE 350?

Millions of Britons invest for a passive income. While our writer isn't buying this stock yet, he believes it's worth…

Read more »

Middle-aged Caucasian woman deep in thought while looking out of the window
Investing Articles

This amazing FTSE 250 has a 8.8% dividend yield and trades at just 4x forward earnings!

Our Foolish writer believes this FTSE 250 stock is worth keeping a very close eye on. However, he's not keen…

Read more »